Biagio Ricciuti

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

4.3Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 39 papers — median percentile 41. Top paper: “Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status”.

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.10.013

N/A

8.9DataRank · unranked

377 citations

Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong +28 more

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3608

N/A

0.811DataRank · unranked

222 citations

Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi +18 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden

Cancer Cell(2023)10.1016/j.ccell.2023.09.006

N/A

0.617DataRank · unranked

60 citations

Jiwoong Kim, Qing Deng, Biagio Ricciuti, Joao V. Alessi, Buse Eglenen-Polat +12 more

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001007

N/A

0.614DataRank · unranked

59 citations

Biagio Ricciuti, E. Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino +10 more

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Cancer Research(2022)10.1158/0008-5472.can-22-1731

N/A

0.564DataRank · unranked

42 citations

Archana Balan, Biagio Ricciuti, Jacob Fiksel, Christopher Cherry, Chenguang Wang +19 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature Communications(2023)10.1038/s41467-023-39874-8

N/A

0.515DataRank · unranked

30 citations

Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti +13 more

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Annals of Oncology(2024)10.1016/j.annonc.2024.11.014

N/A

0.489DataRank · unranked

25 citations

Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti +43 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The Oncologist(2023)10.1093/oncolo/oyad197

N/A

0.385DataRank · unranked

12 citations

Biagio Ricciuti, Joao V. Alessi, Teng Fei, Hannah L. Kalvin, Jacklynn V. Egger +16 more

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.121

N/A

0.373DataRank · unranked

11 citations

Alessandro Di Federico, Bolun Liu, Alissa J. Cooper, Joao V. Alessi, Phoebe Clark +25 more

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1735

N/A

0.345DataRank · unranked

9 citations

Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo +26 more

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007618

N/A

0.330DataRank · unranked

8 citations

Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief +14 more

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w

N/A

0.312DataRank · unranked

7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2990

N/A

0.312DataRank · unranked

7 citations

Rohit Thummalapalli, Stephanie Alden, Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief +18 more

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

Human Genetics and Genomics Advances(2024)10.1016/j.xhgg.2024.100320

N/A

0.269DataRank · unranked

5 citations

Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci +8 more

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100759

Top 59%

0.258DataRank

Top 59%4 citations

Andrea Arfè, Biagio Ricciuti, Andréanne Gagné, Lynette M. Sholl, Alessandro Di Federico +19 more

Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.09.18.613595

N/A

0.104DataRank · unranked

1 citations

Georgia L. Stirtz, Asaf Tal, Ajit J. Nirmal, N. Besson, Stephanie M. Jones +34 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Research Square(2024)10.21203/rs.3.rs-3782958/v1

N/A

0.104DataRank · unranked

1 citations

Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti +6 more

Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9107

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Jia Luo, Joao Victor Machado Alessi +13 more

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100072

N/A

0DataRank · unranked

5 citations

Nuno Vaz, Biagio Ricciuti, Sarah Clifford, Gianluca DiUbaldi, Dawn Drevers +5 more

Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors

European Journal of Radiology(2020)10.1016/j.ejrad.2020.109275

N/A

0DataRank · unranked

24 citations

Hiroto Hatabu, Biagio Ricciuti, Safiya J. Aijazi, Mark M. Awad, Mizuki Nishino +1 more

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Nature Communications(2024)10.1038/s41467-024-49499-0

N/A

0DataRank · unranked

13 citations

Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi +6 more

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

Cell(2025)10.1016/j.cell.2025.09.021

N/A

0DataRank · unranked

11 citations

Georgia L. Stirtz, Asaf Tal, Ajit J. Nirmal, Kathleen L. Pfaff, Michael P. Manos +39 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0DataRank · unranked

5 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

Federated benchmarking of medical artificial intelligence with MedPerf

Nature Machine Intelligence(2023)10.1038/s42256-023-00652-2

N/A

0DataRank · unranked

153 citations

Renato Umeton, Micah Sheller, Alejandro Aristizábal, Johnu George, Anna Wuest +69 more

Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012205

N/A

0DataRank · unranked

1 citations

Biagio Ricciuti, Arielle Elkrief, Joao V Alessi, Alessandro Di Federico, Federica Pecci +11 more

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

medRxiv(2022)10.1101/2022.12.05.22283131

N/A

0DataRank · unranked

0 citations

Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

Research Square(2022)10.21203/rs.3.rs-2273813/v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Xinan Wang, Giuseppe Lamberti, Arielle Elkrief, Federica Pecci +12 more

Germline variants associated with immunotherapy-related adverse events

medRxiv(2022)10.1101/2022.04.10.22273627

N/A

0DataRank · unranked

0 citations

Sarah Abou Alaiwi, Wenxin Xu, Vivek Naranbhai, Amin H. Nassar, Ziad Bakouny +26 more

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Drugs in Context(2022)10.7573/dic.2022-7-4

N/A

0DataRank · unranked

13 citations

Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci +6 more

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab116

N/A

0DataRank · unranked

68 citations

Biagio Ricciuti, Joao V. Alessi, Tom Nguyen, Mark M. Awad, Xihong Lin +3 more

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

(2023)10.1158/0008-5472.c.6514292.v1

Top 100%

0DataRank

Top 100%0 citations

Archana Balan, Biagio Ricciuti, Jacob Fiksel, Christopher Cherry, Chenguang Wang +19 more

Data from Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer

(2023)10.1158/0008-5472.c.6513225.v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Tom C. Nguyen, Xihao Li, Michael S. Rabin, Mark M. Awad +4 more

Biagio Ricciuti

Indexed papers

Top data-sharing exemplar

Papers